Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar Mania Clear all
Completed Phase 3 Interventional Results available

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

NCT00312494
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

NCT00422123
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

NCT00488618
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Cariprazine (RGH-188), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Jul 23, 2026, 11:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Sex Hormones on Circadian Rhythm in Men and Women

NCT00001285
View directory record Official record
Conditions
Bipolar Disorder, Circadian Rhythm, Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania

NCT03383874
View directory record Official record
Conditions
Mania (Neurotic)
Interventions
Probio-Tec BG-VCap-6.5, Placebo
Combination Product · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 23, 2026, 11:14 AM EDT
Terminated Phase 4 Interventional

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
15
States / cities
Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine for Bipolar I Disorder

NCT01058668
View directory record Official record
Conditions
Mania, Bipolar I Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920
View directory record Official record
Conditions
Bipolar Disorder With Manic or Mixed Episodes
Interventions
MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Results available

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCT00982020
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lauderhill, Florida • Bloomfield Hills, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Results available

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

NCT00571688
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal (risperidone) Consta, Treatment as usual
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Jul 23, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

NCT00109577
View directory record Official record
Conditions
Bipolar Disorder
Interventions
MCN36 (nutritional supplement), Placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Research Study of Bipolar Mood Symptoms and Cognitive Problems

NCT00428298
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood Disorders

NCT00001545
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorder, Unipolar Depression
Interventions
Magstim Super Rapid Magnetic Stimulator, Cadwell MES-10
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2006 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00107731
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Acute Bipolar Mania

NCT00097266
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Aripiprazole, Haloperidol
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 23, 2026, 11:14 AM EDT
Terminated Phase 1 Interventional

Taurine in Adolescents With Bipolar Disorder

NCT00391001
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Taurine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
13 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Lithium for the Treatment of Pediatric Mania

NCT00442039
View directory record Official record
Conditions
Bipolar I Disorder Without Psychotic Symptoms
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

NCT00057681
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium carbonate, Valproate, Risperidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 15 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents

NCT00195767
View directory record Official record
Conditions
Bipolar I Disorder, Manic or Mixed
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
10 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Jul 23, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Uridine for Treatment of Bipolar Depression in Adolescents

NCT00841269
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Uridine
Drug
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Jul 23, 2026, 11:14 AM EDT